Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Jul;26(1):23–29. doi: 10.1111/j.1365-2125.1988.tb03359.x

In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.

D J Back 1, J F Tjia 1, J Karbwang 1, J Colbert 1
PMCID: PMC1386495  PMID: 3203057

Abstract

1. A number of compounds have been examined for their ability to inhibit tolbutamide hydroxylase activity in human liver microsomes (control value at a substrate concentration of 150 microM being 0.27 +/- 0.12 nmol min-1 mg-1 protein; mean +/- s.d.; n = 7). 2. IC50 (concentration of inhibitor producing 50% inhibition) values were determined for a range of sulphonamides, imidazoles and aminoquinoline compounds. The most potent inhibition was evident with the 1-substituted imidazole antimycotic drugs ketoconazole, clotrimazole and miconazole and the sulphonamide sulphaphenazole (IC50 values of 16.5, 2.5, 0.85 and 0.5 microM respectively). A number of compounds showed little or no inhibition of tolbutamide hydroxylase as judged by an IC50 of greater than or equal to 500 microM. 3. The Km value for tolbutamide hydroxylase was 125 microM and Vmax, 0.44 nmol min-1 mg-1 protein. All the substituted imidazoles examined in kinetic studies 1v vs 1s, Line-weaver-Burk plots) produced either non-competitive or mixed inhibition. The sulphonamides exhibited competitive inhibition, the Ki for sulphaphenazole being 0.22 microM. Primaquine showed mixed inhibition. Dixon plots confirmed the type of inhibition produced. 4. Although the competitive inhibition between some sulphonamides and tolbutamide is consistent with metabolism by the same isozyme of cytochrome P-450 it does not prove it and further studies with purified enzymes will be necessary to confirm this.

Full text

PDF
23

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Back D. B., Park B. K., Tjia J. F., Newby S. N. Sulphaphenazole and drug oxidation in man. Br J Clin Pharmacol. 1983 Oct;16(4):460–461. doi: 10.1111/j.1365-2125.1983.tb02199.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Back D. J., Purba H. S., Park B. K., Ward S. A., Orme M. L. Effect of chloroquine and primaquine on antipyrine metabolism. Br J Clin Pharmacol. 1983 Nov;16(5):497–502. doi: 10.1111/j.1365-2125.1983.tb02206.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Back D. J., Purba H. S., Staiger C., Orme M. L., Breckenridge A. M. Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat. Biochem Pharmacol. 1983 Jan 15;32(2):257–263. doi: 10.1016/0006-2952(83)90553-1. [DOI] [PubMed] [Google Scholar]
  4. Back D. J., Sutcliffe F., Tjia J. F. Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat. Br J Pharmacol. 1984 Mar;81(3):557–562. doi: 10.1111/j.1476-5381.1984.tb10109.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Back D. J., Tjia J. F. Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo: evidence for a structure-activity relationship. Br J Pharmacol. 1985 May;85(1):121–126. doi: 10.1111/j.1476-5381.1985.tb08838.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Back D. J., Tjia J., Mönig H., Ohnhaus E. E., Park B. K. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. Eur J Clin Pharmacol. 1988;34(2):157–163. doi: 10.1007/BF00614553. [DOI] [PubMed] [Google Scholar]
  7. Beaune P. H., Kremers P. G., Kaminsky L. S., De Graeve J., Albert A., Guengerich F. P. Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes. Drug Metab Dispos. 1986 Jul-Aug;14(4):437–442. [PubMed] [Google Scholar]
  8. Beaune P., Dansette P., Flinois J. P., Columelli S., Mansuy D., Leroux J. P. Partial purification of human liver cytochrome P 450. Biochem Biophys Res Commun. 1979 Jun 13;88(3):826–832. doi: 10.1016/0006-291x(79)91482-7. [DOI] [PubMed] [Google Scholar]
  9. Brown M. W., Maldonado A. L., Meredith C. G., Speeg K. V., Jr Effect of ketoconazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther. 1985 Mar;37(3):290–297. doi: 10.1038/clpt.1985.42. [DOI] [PubMed] [Google Scholar]
  10. CHRISTENSEN L. K., HANSEN J. M., KRISTENSEN M. SULPHAPHENAZOLE-INDUCED HYPOGLYCAEMIC ATTACKS IN TOLBUTAMIDE-TREATED DIABETICS. Lancet. 1963 Dec 21;2(7321):1298–1301. doi: 10.1016/s0140-6736(63)90847-x. [DOI] [PubMed] [Google Scholar]
  11. Cate E. W., Rogers J. F., Powell J. R. Inhibition of tolbutamide elimination by cimetidine but not ranitidine. J Clin Pharmacol. 1986 May-Jun;26(5):372–377. doi: 10.1002/j.1552-4604.1986.tb03540.x. [DOI] [PubMed] [Google Scholar]
  12. Cockburn I. Cyclosporine A: a clinical evaluation of drug interactions. Transplant Proc. 1986 Dec;18(6 Suppl 5):50–55. [PubMed] [Google Scholar]
  13. DIXON M. The determination of enzyme inhibitor constants. Biochem J. 1953 Aug;55(1):170–171. doi: 10.1042/bj0550170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dey N. G., Castleden C. M., Ward J., Cornhill J., McBurney A. The effect of cimetidine on tolbutamide kinetics. Br J Clin Pharmacol. 1983 Oct;16(4):438–440. doi: 10.1111/j.1365-2125.1983.tb02192.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Distlerath L. M., Reilly P. E., Martin M. V., Davis G. G., Wilkinson G. R., Guengerich F. P. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem. 1985 Jul 25;260(15):9057–9067. [PubMed] [Google Scholar]
  16. Guengerich F. P., Müller-Enoch D., Blair I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol. 1986 Sep;30(3):287–295. [PubMed] [Google Scholar]
  17. Guengerich F. P., Umbenhauer D. R., Churchill P. F., Beaune P. H., Böcker R., Knodell R. G., Martin M. V., Lloyd R. S. Polymorphism of human cytochrome P-450. Xenobiotica. 1987 Mar;17(3):311–316. doi: 10.3109/00498258709043941. [DOI] [PubMed] [Google Scholar]
  18. Hall S. D., Guengerich F. P., Branch R. A., Wilkinson G. R. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther. 1987 Jan;240(1):216–222. [PubMed] [Google Scholar]
  19. Inaba T., Jurima M., Mahon W. A., Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos. 1985 Jul-Aug;13(4):443–448. [PubMed] [Google Scholar]
  20. Kalow W. Genetic variation in the human hepatic cytochrome P-450 system. Eur J Clin Pharmacol. 1987;31(6):633–641. doi: 10.1007/BF00541288. [DOI] [PubMed] [Google Scholar]
  21. Knodell R. G., Hall S. D., Wilkinson G. R., Guengerich F. P. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther. 1987 Jun;241(3):1112–1119. [PubMed] [Google Scholar]
  22. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  23. Lavrijsen K., van Houdt J., Thijs D., Meuldermans W., Heykants J. Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes. Xenobiotica. 1987 Jan;17(1):45–57. doi: 10.3109/00498258709047174. [DOI] [PubMed] [Google Scholar]
  24. Lumholtz B., Siersbaek-Nielsen K., Skovsted L., Kampmann J., Hansen J. M. Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism. Clin Pharmacol Ther. 1975 Jun;17(6):731–734. doi: 10.1002/cpt1975176731. [DOI] [PubMed] [Google Scholar]
  25. Meredith C. G., Maldonado A. L., Speeg K. V., Jr The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metab Dispos. 1985 Mar-Apr;13(2):156–162. [PubMed] [Google Scholar]
  26. Mihaly G. W., Ward S. A., Nicholl D. D., Edwards G., Breckenridge A. M. The effects of primaquine stereoisomers and metabolites on drug metabolism in the isolated perfused rat liver and in vitro rat liver microsomes. Biochem Pharmacol. 1985 Feb 1;34(3):331–336. doi: 10.1016/0006-2952(85)90040-1. [DOI] [PubMed] [Google Scholar]
  27. Murray M. In vitro effects of quinoline derivatives on cytochrome P-450 and aminopyrine N-demethylase activity in rat hepatic microsomes. Biochem Pharmacol. 1984 Oct 15;33(20):3277–3281. doi: 10.1016/0006-2952(84)90090-x. [DOI] [PubMed] [Google Scholar]
  28. OMURA T., SATO R. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964 Jul;239:2370–2378. [PubMed] [Google Scholar]
  29. Pond S. M., Birkett D. J., Wade D. N. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):573–579. doi: 10.1002/cpt1977225part1573. [DOI] [PubMed] [Google Scholar]
  30. Purba H. S., Back D. J., Orme M. L. Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors. Br J Clin Pharmacol. 1987 Aug;24(2):230–234. doi: 10.1111/j.1365-2125.1987.tb03167.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Purba H. S., Maggs J. L., Orme M. L., Back D. J., Park B. K. The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol. 1987 Apr;23(4):447–453. doi: 10.1111/j.1365-2125.1987.tb03074.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Riviere J. H., Back D. J. Effect of mefloquine on hepatic drug metabolism in the rat: comparative study with primaquine. Biochem Pharmacol. 1985 Feb 15;34(4):567–571. doi: 10.1016/0006-2952(85)90191-1. [DOI] [PubMed] [Google Scholar]
  33. Riviere J. H., Back D. J. Inhibition of ethinyloestradiol and tolbutamide metabolism by quinoline derivatives in vitro. Chem Biol Interact. 1986 Oct 1;59(3):301–308. doi: 10.1016/s0009-2797(86)80075-8. [DOI] [PubMed] [Google Scholar]
  34. Sheets J. J., Mason J. I. Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver. Drug Metab Dispos. 1984 Sep-Oct;12(5):603–606. [PubMed] [Google Scholar]
  35. Sheets J. J., Mason J. I., Wise C. A., Estabrook R. W. Inhibition of rat liver microsomal cytochrome P-450 steroid hydroxylase reactions by imidazole antimycotic agents. Biochem Pharmacol. 1986 Feb 1;35(3):487–491. doi: 10.1016/0006-2952(86)90224-8. [DOI] [PubMed] [Google Scholar]
  36. Stockley C., Keal J., Rolan P., Bochner F., Somogyi A. Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. Eur J Clin Pharmacol. 1986;31(2):235–237. doi: 10.1007/BF00606666. [DOI] [PubMed] [Google Scholar]
  37. Thabrew M. I., Ioannides C. Inhibition of rat hepatic mixed function oxidases by antimalarial drugs: selectivity for cytochromes P-450 and P-448. Chem Biol Interact. 1984 Oct;51(3):285–294. doi: 10.1016/0009-2797(84)90154-6. [DOI] [PubMed] [Google Scholar]
  38. Wang P. P., Beaune P., Kaminsky L. S., Dannan G. A., Kadlubar F. F., Larrey D., Guengerich F. P. Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry. 1983 Nov 8;22(23):5375–5383. doi: 10.1021/bi00292a019. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES